BioAdaptives

BioAdaptives EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of BioAdaptives (BDPT) as of Oct 25, 2026 is -0.69. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -1.40 — a change of -50.56% (higher).

EV/FCF

-0.69

YoY

-50.56%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of BioAdaptives is 2025 -0.69 . EV/FCF (Enterprise Value to Free Cash Flow) of BioAdaptives was 2024 -1.40 . It decreases by -50.56% higher compared to the previous year.

The BioAdaptives EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-0.43 USD
Jan 1, 2019
-2.98 USD
Jan 1, 2020
-5.82 USD
Jan 1, 2021
-3.14 USD
Jan 1, 2022
-2.25 USD
Jan 1, 2023
-1.84 USD
Jan 1, 2024
-1.40 USD
Jan 1, 2025
-0.69 USD
The BioAdaptives EV/FCF history
YEAREV/FCFYoY
-0.69-50.56%
-1.40-23.97%
-1.84-17.97%
-2.25-28.38%
-3.14-46.08%
-5.82+95.23%
-2.98+598.09%
-0.43-99.84%
-260.26-1,192.02%
23.83-101.23%
-1,932.51+107,242.18%
-1.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

EV/FCF (Enterprise Value to Free Cash Flow) of BioAdaptives is -0.69 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of BioAdaptives changed from -1.40 to -0.69, representing a -50.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s BioAdaptives with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioAdaptives

All Key Metrics — BioAdaptives